Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Neutral
Key Numbers
Market Cap
$22B
P/E
40
Revenue Growth
+3.0%
Gross Margin
N/A
ROE
N/A
About Illumina Inc.
As a mid-cap biotech company trading on the NASDAQ, Illumina Inc. has established itself, with direct, concentrated exposure to the biotech and genomics theme. Gene sequencing platform leader enabling genomics research and clinical testing. Valued at 40x trailing earnings with a $22B market capitalization, the company demonstrates measured expansion at +3% year-over-year.
Expert Coverage
Unlock Full ILMN Analysis
Expert analysis and coverage for Illumina Inc.
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-08-18
More in Biotech & Genomics
LLY
Eli Lilly and Company
91
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65DXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55REGN
Regeneron Pharmaceuticals
88
True North
Pure Play
Biotech powerhouse with strong antibody pipeline and Dupixent franchise.
NASDAQ
MCap $100BRev +7%P/E 22ALNY
Alnylam Pharmaceuticals
88
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%